An observational study in Acute Heart Failure and Reduced Systolic Function, sponsored by Giresun University. Completed. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-06-08.
Sponsored by Giresun University · Observational
All consecutive patients admitted to the intensive care unit (ICU) with ADHF between January 2017 and December 2021 were enrolled in this retrospective study. All-cause mortality and MACE were assessed with respect to relationships with eosinophil indices, including neutrophil-to-eosinophil ratio (NER), leukocyte-to-eosinophil ratio (LER), eosinophil-to-lymphocyte ratio (ELR), and eosinophil-to-monocyte ratio (EMR).
All consecutive patients admitted to the intensive care unit (ICU) with ADHF and reduced EF between January 2017 and December 2021 were enrolled in this retrospective study. HFrEF was defined as having an LVEF of ≤40%. Demographic data were retrieved from patient charts and the institutional digital database. Patients with an LVEF >40%, NYHA Class I and II subjects, those with advanced liver, kidney diseases or malignancies, patients in whom life expectancy was extremely short and patients with autoimmune, allergic, or infectious diseases that affect the eosinophil indices were not included in the study. The study was approved by the local ethics committee.
Conventional guidelines had been followed for the in-hospital treatment of all patients with ADHF, including loop diuretics, vasodilators, inotropes/vasopressors [9]. Blood tests including complete blood count, blood urea nitrogen and creatinine, electrolytes, liver enzymes, and NT-pro BNP were ordered upon admission to the ICU. All patients underwent transthoracic echocardiography. LVEF was measured with 2-dimensional echocardiography via the modified Simpson method [10]. Data concerning 6-month all-cause mortality and MACE were retrieved from the institutional digital database. The definition of MACE was the composite of total death and re-hospitalization for HF within 6 months of initial hospitalization.
The primary outcome measure of this study was all-cause mortality within the first 6 months of index hospitalization and its relationship with eosinophil indices, including NER, LER, ELR and EMR. The secondary outcome measure of this study was the assessment of MACE within the first 6 months of index hospitalization and its association with eosinophil indices.
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's enrollment of 395 is above the median of 200 across 1,679 observational studies indexed under Heart Failure.
Browse Heart Failure studies →Giresun University is the lead sponsor of 51 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Acute decompensated heart failure
Exclusion Criteria:
patients with all-cause mortality within the first 6 months of index hospitalization and MACE (major adverse cardiovascular events)
Diagnostic Test: eosinophil and other hematological parameters
patients without all-cause mortality within the first 6 months of index hospitalization and MACE (major adverse cardiovascular events)
Diagnostic Test: eosinophil and other hematological parameters
mortality
all-cause mortality
Time frame: within the first 6 months of index hospitalization
MACE
major adverse cardiovascular events
Time frame: within the first 6 months of index hospitalization
No study locations are listed for this record.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Giresun University